Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary P Wang

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Drugs|November 7, 2022
Correction to: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile InfectionSahil Khanna, Maha Assi, Christine Lee, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 28, 2020
Baseline Gut Microbiota Composition Is Associated with Major Infections Early after Hematopoietic Cell TransplantationHemant S Murthy, Raad Z Gharaibeh, Zeina Al-Mansour, et al.
Scientific Reports|February 18, 2018
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infectionGary P Wang, Norah Terrault, Jacqueline D Reeves, et al.
Frontiers in Physiology|April 28, 2017
Shifts in the Gut Microbiota Composition Due to Depleted Bone Marrow Beta Adrenergic Signaling Are Associated with Suppressed Inflammatory Transcriptional Networks in the Mouse ColonTao Yang, Niousha Ahmari, Jordan T Schmidt, et al.
Journal of Hepatology|May 23, 2021
Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvirGary P Wang, Gretja L Schnell, Jens J Kort, et al.
The New England Journal of Medicine|July 28, 2010
Efficacy of gene therapy for X-linked severe combined immunodeficiencySalima Hacein-Bey-Abina, Julia Hauer, Annick Lim, et al.
Medrxiv : the Preprint Server for Health Sciences|May 15, 2024
PAM-free diagnostics with diverse type V CRISPR-Cas systemsSantosh R Rananaware, Katelyn S Meister, Grace M Shoemaker, et al.
Gastroenterology|August 12, 2019
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir TherapyAnna S Lok, Mark S Sulkowski, Jens J Kort, et al.
Journal of Lipid Research|October 6, 2019
Decreased ω-6:ω-3 PUFA ratio attenuates ethanol-induced alterations in intestinal homeostasis, microbiota, and liver injuryDennis R Warner, Jeffrey B Warner, Josiah E Hardesty, et al.
Hepatology Communications|February 7, 2018
Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic reviewSofia R Bartlett, Jason Grebely, Auda A Eltahla, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Drugs|November 7, 2022
Correction to: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile InfectionSahil Khanna, Maha Assi, Christine Lee, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 28, 2020
Baseline Gut Microbiota Composition Is Associated with Major Infections Early after Hematopoietic Cell TransplantationHemant S Murthy, Raad Z Gharaibeh, Zeina Al-Mansour, et al.
Scientific Reports|February 18, 2018
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infectionGary P Wang, Norah Terrault, Jacqueline D Reeves, et al.
Frontiers in Physiology|April 28, 2017
Shifts in the Gut Microbiota Composition Due to Depleted Bone Marrow Beta Adrenergic Signaling Are Associated with Suppressed Inflammatory Transcriptional Networks in the Mouse ColonTao Yang, Niousha Ahmari, Jordan T Schmidt, et al.
Journal of Hepatology|May 23, 2021
Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvirGary P Wang, Gretja L Schnell, Jens J Kort, et al.
The New England Journal of Medicine|July 28, 2010
Efficacy of gene therapy for X-linked severe combined immunodeficiencySalima Hacein-Bey-Abina, Julia Hauer, Annick Lim, et al.
Medrxiv : the Preprint Server for Health Sciences|May 15, 2024
PAM-free diagnostics with diverse type V CRISPR-Cas systemsSantosh R Rananaware, Katelyn S Meister, Grace M Shoemaker, et al.
Gastroenterology|August 12, 2019
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir TherapyAnna S Lok, Mark S Sulkowski, Jens J Kort, et al.
Journal of Lipid Research|October 6, 2019
Decreased ω-6:ω-3 PUFA ratio attenuates ethanol-induced alterations in intestinal homeostasis, microbiota, and liver injuryDennis R Warner, Jeffrey B Warner, Josiah E Hardesty, et al.
Hepatology Communications|February 7, 2018
Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic reviewSofia R Bartlett, Jason Grebely, Auda A Eltahla, et al.
Pageof 6